Photodistributed Hyperpigmentation Induced by Lercanidipine
DOI:
https://doi.org/10.17140/DRMTOJ-3-128Abstract
Hypertension (systolic blood pressure of 140 mmHg or above
and/or diastolic blood pressure of 90 mmHg or above), is
the most common chronic condition dealt with by primary care
physicians and other health practitioners.1 Calcium channel blockers
(CCBs), introduced into clinical medicine in the 1960s, are a
group of compounds with distinctive structures and pharmacologic
effects, are first-line treatment option for hypertension.2 In
spite of their widespread use, little data have been published about
the spectrum of cutaneous adverse reactions by CCBs.3-6 Cutaneous
adverse reactions induced by lercanidipine, a third-generation
o dihydropyridine CCBs, are uncommon.7-9 We present to our
knowledge the first case of reticulated photodistributed hyperpigmentation
induced by this drug.
References
Weber MA, Schiffrin EL, White WB, et al. ASH hypertension guidelines. J Clin Hypertens. 2014; 16: 14-26. doi: 10.1111/jch.12237
Sica DA. Pharmacotherapy Review: Calcium channel blockers. J Clin Hypertens. 2006; 8: 53-56. doi: 10.1111/j.1524- 6175.2005.04140.x
Stern R, Khalsa JH. Cutaneous adverse reactions associated with calcium cannel blockers. Arch Inter Med. 1989; 149: 829-832. doi: 10.1001/archinte.1989.00390040057011
Palamaras I, Kyriakis K. Calcium antagonist in dermatology: A review of the evidence and research-based studies. Dermatol Online J. 2005; 11(2): 8.
Kitamura K, Kanasashi M, Suga C, Saito S, Yoshida S, Ikezawa Z. Cutaneous reactions induced by calcium channel blocker: High frequency of psoriasiform eruptions. J Dermatol. 1993; 20: 279-286. doi: 10.1111/j.1346-8138.1993.tb01392.x
Ioulios P, Charalampos M, Efrossini T. The spectrum of cutaneous reactions associated with calcium antagonists: A review of the literature and the possible etiopathogenic mechanisms. Dermatol Online J. 2003; 9: 6.
Slim R, Fathallah N, Larif S, Ben Salem C. Drug reaction with eosinophilia and systemic symptoms due to lercanidipine. Indian J Dermatol Venereol Leprol. 2016; 82: 324-326. doi: 10.4103/0378- 6323.175914
Tuchinda P, Kulthanan K, Khankham S, Jongjarearnprasert K, Dhana N. Cutaneous adverse reactions to calcium channel blockers. Asian Pac J Allergy Immunol. 2014; 32: 246-250. doi: 10.12932/AP0380.32.3.2014
Charfi O, Lakhoua G, Sahnoun R, et al. Bullous eruption associated with dihydropyridines with cross reactivity. Therapie. 2015; 70: 381-383. doi: 10.2515/therapie/2015023
Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001; 2(4): 253-262. doi: 10.2165/00128071-200102040-00006
Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin. 1999; 17: 537-560. doi: 10.1016/S0733-8635(05)70106-6
Lerner EA, Sober AJ. Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin. Dermatol Clin. 1988; 6: 327-337.
Vázquez-Bayo C, Rodríguez-Bujaldón AL, Jiménez-Puya R, Galán-Gutiérrez M, Moreno-Giménez JC. Capecitabine-induced hyperpigmentation. Actas Dermosifiliogr. 2007; 98: 491-493.
Li CC, Malik SM, Blaeser BF, et al. Mucosal pigmentation caused by imatinib: Report of three cases. Head Neck Pathol. 2012; 6: 290-295. doi: 10.1007/s12105-011-0325-4
Kauzman A, Pavone M, Blanas N, Bradley G. Pigmented lesions of the oral cavity: Review, differential diagnosis, and case presentations. J Can Dent Assoc. 2004; 70: 682-683.
Meleti M, Vescovi P, Mooi WJ, van der Waal I. Pigmented lesions of the oral mucosa and perioral tissues: A flow-chart for the diagnosis and some recommendations for the management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105: 606- 616. doi: 10.1016/j.tripleo.2007.07.047
Jaworski K, Walecka I, Rudnicka L, Gnatowski M, Kosior DA. Cutaneous adverse reactions of amiodarone. Med Sci Monit. 2014; 20: 2369-2372. doi: 10.12659/MSM.890881
Boyer M, RajaniKatta MD, Ramsey Markus MD. DiltiazemSubmit your article to this journal | https://openventio.org/submit-manuscript/ induced photodistributed hyperpigmentation. Dermatol Online J. 2003; 9(5): 10.
Kubo Y, Fukumoto D, Ishigami T, Hida Y, Arase S. Diltiazemassociated photodistributed hyperpigmentation: Report of two Japanese cases and published work review. J Dermatol. 2010; 37(9): 807-811. doi: 10.1111/j.1346-8138.2010.00858.x
Erbagci Z. Amlodipine associated hyperpigmentation. Saudi Med J. 2004; 25: 103-105.
Hanson M, Petronic-Rosic V. Reticulated phototoxic eruption in a patient on long-term diltiazem therapy. J Drugs Dermatol. 2008; 7: 792-793.
Scherschun L, Lee MW, Lim HW. Diltiazem-associated photodistributed hyperpigmentation: Review of 4 cases. Arch Dermatol. 2001; 137(2): 179-182.
Chawla A, Goyal S. Diltiazem-induced hyperpigmentation in an African American woman. J Am Acad Dermatol. 2002; 46: 468- 469. doi: 10.1067/mjd.2002.118359
Boyer M, Katta R, Markus R. Diltiazem-induced photodistributed hyperpigmentation. Dermatol Online J. 2003; 9: 10.
Giménez-García R. Hyperpigmentation induced by combination therapy with telmisartan-hydrochlorothiazide. J Clin Hypertens (Greenwich). 2016; 18: 361-362. doi: 10.1111/jch.12665
Beckey Ch Lercanidipine in the treatment of hypertension. Ann Pharmacother. 2007; 41: 465-474. doi: 10.1345/aph.1H299
Borgui C. Lercanidipine in hypertension. Vasc Health Risk Manag. 2005; 2005: 173-182.
Mc Clellan KJ. Lercanidipine: A review of its use in hypertension. Drugs. 2000; 60(5): 1123-1140.
Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A; COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002; 15(11): 932-940. doi: 10.1016/S0895-7061(02)03000-5
Moore DE. Drug-induced cutaneous photosensitivity: Incidence, mechanism, prevention and management. Drug Saf. 2002; 25: 345-372. doi: 10.2165/00002018-200225050-00004
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Dermatology (DER) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
